Natural Capsules Q1FY27: consolidated loss ₹5.7 Cr on API drag; standalone PAT +60% YoY
PAT -2.93% YoY · revenue +7.76% · margins flat
₹48.71 Cr
+7.76% YoY
₹-5.74 Cr
-2.93% YoY
-11.25%
+1pp YoY
₹-5.55
Consolidated (primary basis) Natural Capsules posted a net loss of ₹5.74 Cr on revenue of ₹48.71 Cr for Q1 FY27 — revenue up 7.8% YoY but down 16.7% QoQ against a seasonally strong Q4. The loss is marginally wider than the ₹5.58 Cr loss a year ago (+2.9%) and meaningfully wider than the ₹4.98 Cr loss last quarter (+15.4%), leaving consolidated NPM roughly flat YoY at -11.8% (vs -12.3%) but compressed sharply QoQ (vs -8.4% in Q4). Standalone tells a very different story: standalone PAT of ₹4.04 Cr is up 59.9% YoY on PBT growth of 62.9%, underscoring that the entire consolidated drag sits in the API subsidiaries (Natural Phyto Pharma, Natural Biogenex) — a >3% divergence between the two bases that readers should note rather than assume an error.
Q1 FY-2027 vs prior quarters
The margin bridge: segment result before interest and tax improved 56% YoY to -₹0.94 Cr (from -₹2.15 Cr), driven by the Capsules segment's PBIT rising 46.9% YoY to ₹7.10 Cr — consistent with management's stated push for HPMC/Gelatin margin improvement. That operating gain was largely offset by finance costs, which rose 24.5% YoY to ₹4.97 Cr, and by the API segment, whose loss widened 15.1% YoY to ₹8.04 Cr even as API revenue grew nearly 6x YoY (₹5.69 Cr vs ₹0.96 Cr) off a low base — in line with management's own framing that the API business would run negative EBITDA while scaling, with improvement over time rather than immediate profitability.
The stock went into the print at ₹158.59, up 10.6% over the past month of trading.
Management projects FY27 revenue of approximately Rs. 274 crores, with Rs. 170 crores from Gelatin capsules, Rs. 20 crores from HPMC capsules, Rs. 70 crores from domestic API sales, and Rs. 14 crores from Fermbox contract manufacturing. For the capsules business, they expect EBITDA margins of 18% for HPMC and 13% for G
— This quarter: missed
On management's FY27 guidance (₹274 Cr revenue: ₹170 Cr Gelatin, ₹20 Cr HPMC, ₹70 Cr domestic API, ₹14 Cr Fermbox — no external street estimates exist for this micro-cap, so no vs-street read is available): the Capsules segment's Q1 revenue of ₹43.02 Cr annualises to roughly ₹172 Cr, near the ₹190 Cr combined Gelatin+HPMC target, but the API segment's ₹5.69 Cr annualises to only ~₹23 Cr against the ₹70 Cr domestic API target — well off pace. Fermbox contract manufacturing isn't broken out as a separate segment in this filing, so its progress can't be verified from the numbers. No formal press release accompanied this filing.
W1
API segment loss trajectory: ₹8.04 Cr this quarter vs ₹9.35 Cr (Q4FY26) and ₹6.99 Cr (Q1FY26) — watch whether losses narrow toward management's 'improving over time' framing
W2
API domestic sales run-rate needs to scale from ~₹5.69 Cr/quarter toward the ₹70 Cr FY27 target — current pace implies a large back-half ramp is required
W3
Finance cost trend (₹4.97 Cr this quarter, +24.5% YoY) and whether the new ~₹10 Cr promoter warrant/preferential raise (EGM September 9, 2026) is used to pare debt
No exceptional items either period. Consolidated PAT includes non-controlling interest (-1.7676 Cr to minority, -3.9762 Cr to shareholders); tables clean, figures cross-check exactly against DB comparison context, converted Lakh→Crore throughout.